Company Filing History:
Years Active: 2015
Title: Inventor Spotlight: Steffen Runz and His Breakthrough in Osteoclast Research
Introduction: Steffen Runz, an innovative inventor located in Martinsried/Planegg, Germany, has made significant contributions to the field of antibody development. With one notable patent under his name, his work focuses on targeting osteoclast-related proteins to advance therapeutic options for bone-related conditions.
Latest Patents: Steffen Runz's primary patent is titled "Antibody targeting osteoclast-related protein Siglec-15." This invention describes an isolated antibody capable of binding Siglec-15, which inhibits osteoclast formation and/or osteoclastic bone resorption. The detailed structure of the antibody includes specific sequences for its heavy and light chains, allowing for precise targeting of the Siglec-15 protein, thereby enhancing its therapeutic potential.
Career Highlights: Steffen Runz is currently employed at Daiichi Sankyo Company, Limited, where he engages in pioneering research and development. His expertise and focus on monoclonal antibodies position him as a pivotal contributor to the company's innovations in biopharmaceuticals.
Collaborations: Throughout his career, Steffen has collaborated with notable colleagues, including Ichiro Watanabe and Yoshiharu Hiruma. These partnerships not only enhance the diversity of ideas but also drive forward the research initiatives within their field, benefiting from a collective knowledge base and shared goals.
Conclusion: As an inventor, Steffen Runz exemplifies the spirit of innovation in the biopharmaceutical sector. His patented work on antibodies targeting Siglec-15 marks an important advancement in understanding osteoclast regulation and opens avenues for potential therapies in bone health. His continued efforts at Daiichi Sankyo Company, Limited signify a dedication to advancing medical science and improving patient outcomes.